However, the study did not specifically assess early initiation of biologics or include cognitive outcomes as primary endpoints, and no randomized clinical trials have yet examined IL-17 or IL-23 inhibitors for dementia prevention or treatment [35]. This evidence concerns the gene IL17A and dementia.